Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KALANASDAQ:OASMNASDAQ:PHASNASDAQ:SESN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALAKALA BIO$7.84-0.1%$7.35$5.10▼$19.57$21.09M-1.8629,403 shs9,908 shsOASMOasmia Pharmaceutical AB (publ)$0.02$1.46$0.94▼$5.70$1.50M0.9698,414 shsN/APHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs2,910 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALAKALA BIO-0.13%-0.25%+9.65%+12.00%-47.10%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-60.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%-98.57%+25.00%SESNSesen Bio0.00%0.00%0.00%0.00%+1,900.00%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKALAKALA BIO4.4165 of 5 stars3.53.00.04.42.11.71.3OASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALAKALA BIO3.00Buy$22.00180.61% UpsideOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALAKALA BIO$3.89M5.42N/AN/A$11.12 per share0.71OASMOasmia Pharmaceutical AB (publ)$220K6.82N/AN/A$0.63 per share0.03PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALAKALA BIO-$44.82M-$22.73N/AN/AN/AN/A-259.42%-64.39%3/29/2024 (Estimated)OASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/APHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ASESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKALAKALA BION/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALAKALA BIO3.365.625.62OASMOasmia Pharmaceutical AB (publ)N/A0.800.73PHASPhaseBio PharmaceuticalsN/A0.470.47SESNSesen BioN/A6.106.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALAKALA BIO24.61%OASMOasmia Pharmaceutical AB (publ)0.11%PHASPhaseBio Pharmaceuticals49.02%SESNSesen Bio16.45%Insider OwnershipCompanyInsider OwnershipKALAKALA BIO13.40%OASMOasmia Pharmaceutical AB (publ)N/APHASPhaseBio Pharmaceuticals9.90%SESNSesen Bio3.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKALAKALA BIO342.69 million2.33 millionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableSESNSesen Bio35203.49 million196.98 millionOptionableKALA, SESN, OASM, and PHAS HeadlinesSourceHeadlineDevin Haney: biography, record, fights and moreespn.com - December 9 at 5:50 PMTyson Fury: Biography, record, fights and moreespn.com - December 2 at 10:49 AMWhy the Tucker Carlson Biography Sales Are So Patheticthedailybeast.com - September 13 at 10:23 PMSesen Bio (NASDAQ: SESN)fool.com - August 4 at 6:23 PMJames McTeigue Biography & Moviestribute.ca - May 10 at 6:46 PMAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Biobizjournals.com - March 6 at 7:17 PMSesen Bio wins shareholder approval for Carisma mergermsn.com - March 2 at 1:30 PMSesen Bio Stockholders Approve Merger with Carisma Therapeuticsfinance.yahoo.com - March 2 at 1:30 PMSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Resultsfinance.yahoo.com - February 28 at 12:42 PMSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigationsbenzinga.com - February 24 at 9:19 PMLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carismafinance.yahoo.com - February 21 at 10:50 AMBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeuticsstockhouse.com - February 17 at 8:59 PMLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meetingbusinesswire.com - February 16 at 4:47 PMSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Mergerfinance.yahoo.com - February 16 at 9:10 AMSesen Bio reaches deal with investor group, paving way for Carisma mergerendpts.com - February 15 at 2:11 PMLatest terms of Sesen Bio and Carisma merger appear to pass musterthepharmaletter.com - February 15 at 2:11 PM5 big dividend moves: Group 1 Automotive hikes by 20% | Pro Recapfinance.yahoo.com - February 15 at 9:11 AMBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeuticsfinance.yahoo.com - February 15 at 9:11 AMSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupbizjournals.com - February 14 at 2:01 PMSesen gains 11% on amended terms for merger with Carismamsn.com - February 14 at 9:00 AMSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Mergerfinance.yahoo.com - February 14 at 9:00 AMSesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years agofinance.yahoo.com - February 6 at 10:17 AMSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Mergerfinance.yahoo.com - February 2 at 7:29 PMThe Petri Dish: Departed White House adviser returns to the Broadfinance.yahoo.com - February 2 at 9:28 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsKALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Oasmia Pharmaceutical AB (publ)NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Sesen BioNASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.